ADPT · Adaptive Biotechnologies Corpor
$22.31
+1.64% last session
End-of-day data · updated 2026-07-25
Market cap
$4B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
-94.0
Dividend yield
—
Beta
2.07
Avg volume
3M
Employees
1K
2D change
-0.18%
5D change
1.88%
10D change
-2.75%
30D change
9.98%
60D change
57.61%
MTD change
-0.45%
YTD change
37.13%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ADPT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-09
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$20.00
-10.4% vs priceJP Morgan
Overweight$19.00
-14.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Morgan Stanley | Maintains | Equal-Weight | $18.00 → $20.00 |
| 2026-06-29 | Guggenheim | Maintains | Buy | $21.00 → $22.00 |
| 2026-06-17 | BTIG | Reiterates | Buy | $22.00 |
| 2026-05-12 | Morgan Stanley | Maintains | Equal-Weight | $21.00 → $18.00 |
| 2026-05-06 | JP Morgan | Maintains | Overweight | $21.00 → $19.00 |
| 2026-05-06 | TD Cowen | Maintains | Buy | $19.00 → $21.00 |
| 2026-05-06 | Guggenheim | Reiterates | Buy | $21.00 |
| 2026-05-06 | BTIG | Reiterates | Buy | $22.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 23.7% above the 50-day MA ($18.04).
- Price vs 200-day MA: Trading 36.4% above the 200-day MA ($16.36).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.12) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($22.92).
ADPT Price Chart
Loading chart for ADPT…
Fundamentals
About Adaptive Biotechnologies Corpor
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
More in Diagnostics & Research
DHR
Danaher Corporation
$135B -16.0% YTD
IDXX
IDEXX Laboratories, Inc.
$43B -19.5% YTD
A
Agilent Technologies, Inc.
$39B 2.5% YTD
NTRA
Natera, Inc.
$38B 14.4% YTD
WAT
Waters Corporation
$37B -1.4% YTD
IQV
IQVIA Holdings, Inc.
$35B -7.7% YTD
ILMN
Illumina, Inc.
$29B 48.0% YTD
MTD
Mettler-Toledo International, I
$27B -4.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.